Company Encyclopedia
View More
name
Shanghai Pharma
601607.SH
Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and healthcare products in China and internationally. It operates through four segments: Production, Distribution, Retail, and Others. The company offers chemical and biological drugs, Chinese medicine, health care products, and medical devices to treat immunology, psychiatric and neurological, tumor, cardiovascular, digestive metabolism, psychoneurotic, neoplasm, respiratory system, and anti-infection diseases, as well as invests in equity.
402.16 B
601607.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care DistributorsIndustry
Industry Ranking4/25
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE7.70%B
    • Profit Margin2.01%C
    • Gross Margin10.14%E
  • Growth ScoreC
    • Revenue YoY3.04%C
    • Net Profit YoY40.24%B
    • Total Assets YoY5.81%B
    • Net Assets YoY7.77%B
  • Cash ScoreB
    • Cash Flow Margin4972.08%A
    • OCF YoY3.04%C
  • Operating ScoreA
    • Turnover1.22A
  • Debt ScoreD
    • Gearing Ratio62.14%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    HSBC Research: The domestic pharmaceutical industry lacks short-term catalysts, and the target price for Shanghai Pharma and China National Pharmaceutical Group is lowered

    HSBC Research pointed out that the Chinese pharmaceutical industry lacks short-term catalysts, the market recovery is weak, and policies are affecting industry growth. Shanghai Pharma and Sinopharm maintain a "Hold" rating, with target prices lowered to RMB 11.8 and RMB 19.5, respectively. It is expected that the lagging consumption recovery and tightening policies will continue to suppress the industry's short-term upside potential

    AASTOCKS·
    SH
    601607
    +0.06%
    HK
    02607
    +0.75%
    AASTOCKS·
    SH
    601607
    +0.06%
    HK
    02607
    +0.75%

    Morning Trend | Shanghai Pharma remains weak and cautious, when will it welcome policy catalysts?

    Shanghai Pharma (2607.HK) has recently shown weak price consolidation, remaining in a wait-and-see range overall. The daily MACD continues to show a death cross, and the main moving averages are still under pressure, indicating a cautious attitude in capital flow. The pharmaceutical sector lacks strong policy catalysts in the short term, combined with low market risk appetite, leading to a wait-and-see approach from major players. The company's fundamentals are relatively resilient, but increased competitive pressure and periodic policy regulation in the industry have resulted in limited performance growth elasticity. The technical bottom has not yet solidified, and the trading volume remains persistently low, indicating that major funds have not yet flowed in on a large scale. If there are significant policy benefits or industry event catalysts, short-term funds may react, driving a rapid rebound in stock prices. However, in the absence of clear positive factors, it is recommended that investors focus on controlling positions and defense, paying attention to intraday trading anomalies and changes in capital flow direction, and waiting for opportunities to act

    Technical Forecast·
    SH
    601607
    +0.06%
    HK
    02607
    +0.75%
    Technical Forecast·
    SH
    601607
    +0.06%
    HK
    02607
    +0.75%

    UBS: Raises target price for Shanghai Pharma to HKD 15, rating "Buy"

    UBS raised the target price for Shanghai Pharma to HKD 15, with a rating of "Buy." Management stated that in 2025, they will focus on the business transformation of the industrial and commercial sectors, with the former concentrating on innovative drugs and traditional Chinese medicine, and the latter focusing on CSO and innovative drug services. Although the earnings per share forecast for 2025 was raised by 7%, the earnings forecasts for 2026 and 2027 were lowered by 11% and 10%, respectively. In the first three quarters, operating revenue increased by 2.6% year-on-year, and net profit attributable to the parent company increased by 27%

    Zhitong·
    SH
    601607
    +0.06%
    HK
    02607
    +0.75%
    Zhitong·
    SH
    601607
    +0.06%
    HK
    02607
    +0.75%

    Citigroup raises the target price of Shanghai Pharma to 14.2 yuan, maintaining a "Buy" rating

    Citi has lowered its revenue forecast for Shanghai Pharma for the years 2025 to 2027 by 3% to 6% to reflect the ongoing pressure on core business, and has reduced its earnings per share forecast for the same period by 12% to 14%. However, the bank has raised its target price for Shanghai Pharma from RMB 13.1 to RMB 14.2, as the market may underestimate the long-term value created by the company's manufacturing platform strategic restructuring, the huge potential of the commercial insurance market, and the clear progress in cost optimization; maintaining a "Buy" rating

    AASTOCKS·
    SH
    601607
    +0.06%
    HK
    02607
    +0.75%
    AASTOCKS·
    SH
    601607
    +0.06%
    HK
    02607
    +0.75%

    Shanghai Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 5.147 billion yuan, a year-on-year increase of 26.96%

    Shanghai Pharma released its third-quarter report for 2025, achieving operating revenue of 215.072 billion yuan from January to September 2025, a year-on-year increase of 2.60%. The net profit attributable to the parent company was 5.147 billion yuan, a year-on-year increase of 26.96%. The sales revenue of the pharmaceutical industry was 18.164 billion yuan, a year-on-year decrease of 0.66%; the sales revenue of the pharmaceutical business was 196.908 billion yuan, a year-on-year increase of 2.91%. After deducting one-time special gains and losses, the net profit attributable to the parent company was 3.979 billion yuan, a year-on-year decrease of 1.85%. The net cash flow from operating activities was 2.350 billion yuan, continuing to maintain high-quality development

    Zhitong·
    SH
    601607
    +0.06%
    HK
    02607
    +0.75%
    Zhitong·
    SH
    601607
    +0.06%
    HK
    02607
    +0.75%
    © 2025 Longbridge｜Disclaimer